B-cell Malignancy Clinical Trials

18 clinical trials for B-cell Malignancy across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Phase I Study of HRS-1635 in B-cell Malignancies — RECRUITING · PHASE1
• Phase I Study of HRS-3005 in B-cell Malignancies — RECRUITING · PHASE1
• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader — RECRUITING · PHASE1
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies — RECRUITING · PHASE1
• Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ANTI-CD70 ALLOGENIC CRISPR-CAS9-ENGINEERED T CELLS (CTX130) IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY T OR B CELL MALIGNANCIES — RECRUITING · PHASE1
• Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors — SUSPENDED · PHASE1
• A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) — TERMINATED · PHASE1
• CD19-CAR-T in B-cell Malignancies Patients — COMPLETED · PHASE1
• CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients — COMPLETED · PHASE1
• Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies — OTHER · PHASE1
• Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma — OTHER · PHASE1
• Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma — OTHER · PHASE1
• Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies — OTHER · PHASE1
• CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies — OTHER · PHASE1

Refine this search